PROBLEM TO BE SOLVED: To provide an inhibitor against the degeneration or the death of motor cells which comprises troglitazone or its pharmacologically permissible salt. SOLUTION: This inhibitor against the degeneration or the death of motor cells comprises troglitazone or its pharmacologically permissible salt and preferably further comprises IGF-I (insulin-like growth factor) or b-FGF (basic fibroblast growth factor).

The insulin sensitivity enhancers, such as troglitazone, have the ability to treat and/or prevent hyperuricemia. They may be used for treating diseases such as gout, urinary calculus, hyperuricemic nephropathy and Lesch-Nyhan syndrome. Preferred insulin sensitivity enhancers are: i)5-[4-(6-hydroxy-2,5,7,8-tetramethylchroman-2-ylmethoxy)benzyl]thiazolidine-2,4-dione, ii)5-[4-(6-acetoxy-2,5,7,8-tetramethylchroman-2-ylmethoxy)benzyl]thiazolidine-2,4-dione, iii)5-[4-(6-ethoxycarbonyloxy-2,5,7,8-tetr...

Described is the use of troglitazone or a pharmaceutically acceptable salt thereof in the manufacture of a medicament having activity in enhancing glutathione reductase activity for the prevention or treatment of diseases resulting from a deficiency of reduced glutathione, provided that said diseases do not include diabetes, hyperglycemia and complications thereof.

PROBLEM TO BE SOLVED: To obtain the subject inhibitor having excellent apoptosis inhibiting actions by including troglitazone as an active ingredient. SOLUTION: This inhibitor is obtained by including troglitazone or its pharmacologically acceptable salt (e.g. a sodium salt, a calcium salt or an ammonium salt) as an active ingredient. The daily dose of the active ingredient is preferably 0.1-1,000 mg at a time in the case of oral administration and 0.01-500 mg at a time in the case of intravenou...

PURPOSE: A glutathione reductive activity potentiator containing troglitazone or a pharmacologically acceptable salt thereof is provided. CONSTITUTION: Troglitazone having the formula(I) potentiates glutathione reductive activity. The glutathione reductive activity potentiator is used for the prevention or treatment of diseases from reduced glutathione deficiency, diseases from oxidative stress, ischemic heart disease, idiopathic pulmonary fibrosis, chronic renal failure, neurological diseases f...